Olson S C, Ayres J W, Antal E J, Albert K S
J Pharm Sci. 1985 Jul;74(7):735-40. doi: 10.1002/jps.2600740708.
Relative bioavailability and pharmacodynamics of tolbutamide from two different commercially available tablet products have been evaluated in healthy subjects in a single-dose crossover study. "Fresh" tablets and tablets aged by exposure to 98% relative humidity for 3 d at ambient temperature were studied. Aging was found to differentially affect both the rate and extent of absorption for the two products. Differences were reflected by log AUC (generic product AUC 10% lower than the product of the innovator, p = 0.047), peak concentration (generic product 27% lower than the product of the innovator, p = 0.0001), mean absorption time (generic product 119% longer than the product of the innovator, p = 0.0008), and mean residence time (generic product 17% longer than the product of the innovator, p = 0.011). Aged product from the innovator produced statistically significantly higher serum tolbutamide concentrations for the first 8 h postdose and a greater glucose depression than aged generic product. Administration of unaged tablets with food produced differences in the rate of absorption, manifested in time-to-peak (generic product 69% later than the product of the innovator, p = 0.006), peak concentration (generic product 18% lower than the product of the innovator, p = 0.001), and mean absorption time (generic product 104% greater than the product of the innovator, p = 0.007), which resulted in statistically significantly higher tolbutamide concentrations for the product of the innovator than for the generic product for the first 3 h postdose.(ABSTRACT TRUNCATED AT 250 WORDS)
在一项单剂量交叉研究中,已对健康受试者评估了两种不同市售片剂产品中甲苯磺丁脲的相对生物利用度和药效学。研究了“新鲜”片剂以及在环境温度下暴露于98%相对湿度3天的老化片剂。发现老化对两种产品的吸收速率和程度有不同影响。差异体现在对数AUC(仿制药产品AUC比创新药产品低10%,p = 0.047)、峰浓度(仿制药产品比创新药产品低27%,p = 0. = 0.0001)、平均吸收时间(仿制药产品比创新药产品长119%,p = 0.0008)和平均驻留时间(仿制药产品比创新药产品长17%,p = 0.011)上。创新药的老化产品在给药后最初8小时产生的血清甲苯磺丁脲浓度在统计学上显著高于老化仿制药产品,且血糖降低幅度更大。空腹服用未老化片剂会产生吸收速率差异,表现为达峰时间(仿制药产品比创新药产品晚69%,p = 0.006)峰浓度(仿制药产品比创新药产品低18%,p = 0.001)和平均吸收时间(仿制药产品比创新药产品长104%,p = 0.007),这导致给药后最初3小时创新药产品的甲苯磺丁脲浓度在统计学上显著高于仿制药产品。(摘要截断于25字) (注:原文中“p = 0. = 0.0001”疑似有误,译文保留原文形式)